<DOC>
	<DOCNO>NCT01065298</DOCNO>
	<brief_summary>The purpose study improve blood glucose control Type 2 Diabetes mellitus patient .</brief_summary>
	<brief_title>Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2</brief_title>
	<detailed_description>We hypothesize Autologous bone marrow derive stem cell transplantation ( ABMSCT ) pancreas patient T2DM , age 30 - 70 year triple oral hypoglycemic agent failure insulin ( &gt; 0.4 U/ kg body weight/day ) lead abolition reduction insulin requirement equal 50 % patient period 6 month . It assume ABMSCT patient lead increased angiogenesis , secretion various cytokine upregulation pancreatic transcription factor Vascular endothelial growth factor ( VEGF ) create microenvironment support beta cell/resident stem cell activation survival .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Patients type 2 diabetes mellitus 30 70 year age . 2 . Failure triple OHA stable dos insulin atleast 3 month . 3 . On vildagliptin , pioglitazone metformin atleast 3 month along Insulin maintain euglycemia . 4 . HbA1c &lt; 8.5 % . 5 . Insulin requirement â‰¥0.4 IU/kg/d . 6 . GAD antibody negative status . 1 . Patients T1DM secondary diabetes . 2 . Patients serum creatinine &gt; 1.5 mg/dl . 3 . Abnormal liver function test ( define value transaminases &gt; 3 time upper value normal serum bilirubin high normal reference value laboratory ) . 4 . History cholecystitis/ cholelitiasis/ cholecystectomy 5 . Seropositivity HIV , HBsAg HCV . 6 . History myocardial infarction unstable angina previous 3 month . 7 . History malignancy 8 . Patients active infection .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>